DeepMed Research

Neuraly, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding, Subsidiary

Established: 2016-01-01

Employees: 11

Market Cap: -

Website: http://www.neuralymed.com

Clinical Trials

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Phase 2

Active, not recruiting

Conditions: NAFLD
NASH

Interventions: Drug: Placebo
Drug: DD01

First Posted Date: 2024-05-13

Last Posted Date: 2025-04-29

Lead Sponsor: Neuraly, Inc.

Target Recruit Count: 67

Registration Number: NCT06410924

Locations: 🇺🇸
Summit Research Site, San Antonio, Texas, United States

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Phase 1

Completed

Conditions: NAFLD
Overweight and Obesity
Type2 Diabetes

Interventions: Drug: DD01
Drug: Placebo

First Posted Date: 2021-03-23

Last Posted Date: 2024-04-29

Lead Sponsor: Neuraly, Inc.

Target Recruit Count: 255

Registration Number: NCT04812262

Locations: 🇺🇸
Prosciento, Chula Vista, California, United States
🇺🇸
Southwest General Healthcare Center, Fort Myers, Florida, United States
🇵🇷
FDI Clinical Research, San Juan, Puerto Rico

and more 1 locations

A Study With NLY01 in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Type2 Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: NLY01
Drug: Placebo

First Posted Date: 2019-11-12

Last Posted Date: 2021-03-02

Lead Sponsor: Neuraly, Inc.

Target Recruit Count: 20

Registration Number: NCT04159766

Locations: 🇩🇪
Profil Institute, Neuss, Germany
🇩🇪
Profil Institute fur Stoffwechselforschung GmbH, Neuss, Germany

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Phase 2

Active, not recruiting

Conditions: Parkinson Disease

Interventions: Drug: NLY01
Drug: Vehicle

First Posted Date: 2019-11-06

Last Posted Date: 2022-11-17

Lead Sponsor: Neuraly, Inc.

Target Recruit Count: 255

Registration Number: NCT04154072

Locations: 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

and more 58 locations

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

Phase 1

Completed

Conditions: Safety and Tolerability in Healthy Volunteers

Interventions: Drug: NLY01

First Posted Date: 2018-09-14

Last Posted Date: 2019-09-30

Lead Sponsor: Neuraly, Inc.

Target Recruit Count: 96

Registration Number: NCT03672604

Locations: 🇺🇸
ICON Early Phase Services/CRU, San Antonio, Texas, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy